DORA and lemborexant in Alzheimer's biomarkers study
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 65 years old
- Have no signs of dementia or memory loss (CDR score of 0)
- Be willing to undergo study procedures like blood tests and sleep assessments
- Not have untreated or poorly treated sleep apnea
- Not have a history of stroke, kidney or liver problems, or certain sleep disorders like restless legs syndrome
- Not drink alcohol regularly (more than 2 drinks within 3 hours of bedtime, 3+ days a week)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
This trial tests whether daridorexant can improve sleep in people who have mild cognitive impairment or early Alzheimer’s disease and struggle with insomnia. It may help by improving how long and how well you sleep, with monitoring of sleep patterns and memory-related measures.
This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.
This trial tests whether a medication called Lemborexant can improve sleep problems and movement symptoms in people with Parkinson's disease. If you have trouble sleeping due to insomnia and have had Parkinson's for at least 2 years, this study may help.
This trial tests if the sleep medication lemborexant can help people with early-stage dementia who also have insomnia. It uses an N-of-1 design, meaning it will look at how you personally respond to the drug compared to a placebo.
This trial tests whether a medication that blocks brain chemicals involved in wakefulness can help reduce markers of nerve damage in people with insomnia. It is for adults aged 40–65 with chronic insomnia, and it aims to see if improving sleep may protect brain health.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.